Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.

Póti Á, Berta K, Xiao Y, Pipek O, Klus GT, Ried T, Csabai I, Wilcoxen K, Mikule K, Szallasi Z, Szüts D.

Br J Cancer. 2018 Nov;119(11):1392-1400. doi: 10.1038/s41416-018-0312-6. Epub 2018 Nov 14.

PMID:
30425352
2.

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, Lamb ML, Lawson D, Dry JR, Lyne PD, Tate EW, Zinda M, Mikule K, Fawell SE, Reimer C, Chen H.

Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8.

PMID:
30297535
3.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

PMID:
29180466
4.

Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.

Gu C, Lamb ML, Johannes JW, Sylvester MA, Eisman MS, Harrison RA, Hu H, Kazmirski S, Mikule K, Peng B, Su N, Wang W, Ye Q, Zheng X, Lyne PD, Scott DA.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4775-4780. doi: 10.1016/j.bmcl.2016.08.030. Epub 2016 Aug 12.

PMID:
27578247
5.

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T, Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B, Petteruti P, Read JA, Su N, Sylvester M, Throner S, Wang W, Wang X, Wu J, Ye Q, Yu Y, Zheng X, Scott DA.

Bioorg Med Chem Lett. 2015 Dec 15;25(24):5743-7. doi: 10.1016/j.bmcl.2015.10.079. Epub 2015 Oct 27.

PMID:
26546219
6.

Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.

7.

Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.

Yang B, Lamb ML, Zhang T, Hennessy EJ, Grewal G, Sha L, Zambrowski M, Block MH, Dowling JE, Su N, Wu J, Deegan T, Mikule K, Wang W, Kaspera R, Chuaqui C, Chen H.

J Med Chem. 2014 Dec 11;57(23):9958-70. doi: 10.1021/jm501179r. Epub 2014 Dec 2.

PMID:
25458601
8.

Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.

Wu J, Mikule K, Wang W, Su N, Petteruti P, Gharahdaghi F, Code E, Zhu X, Jacques K, Lai Z, Yang B, Lamb ML, Chuaqui C, Keen N, Chen H.

ACS Chem Biol. 2013 Oct 18;8(10):2201-8. doi: 10.1021/cb400186w. Epub 2013 Aug 16.

PMID:
23895133
9.

The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions.

Blazkova H, von Schubert C, Mikule K, Schwab R, Angliker N, Schmuckli-Maurer J, Fernandez PC, Doxsey S, Dobbelaere DA.

Cell Cycle. 2007 Oct 15;6(20):2531-40. Epub 2007 Jul 30.

PMID:
17704647
10.

Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest.

Mikule K, Delaval B, Kaldis P, Jurcyzk A, Hergert P, Doxsey S.

Nat Cell Biol. 2007 Feb;9(2):160-70.

PMID:
17330329
11.

Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.

Sun X, Li Y, Li W, Zhang B, Wang AJ, Sun J, Mikule K, Jiang Z, Li CJ.

Cell Cycle. 2006 Sep;5(17):2029-35. Epub 2006 Sep 1.

PMID:
16969131
12.

Centrosome control of the cell cycle.

Doxsey S, Zimmerman W, Mikule K.

Trends Cell Biol. 2005 Jun;15(6):303-11. Review.

PMID:
15953548
13.

Eicosanoid activation of protein kinase C epsilon: involvement in growth cone repellent signaling.

Mikule K, Sunpaweravong S, Gatlin JC, Pfenninger KH.

J Biol Chem. 2003 Jun 6;278(23):21168-77. Epub 2003 Mar 28.

14.

Growth cone collapse induced by semaphorin 3A requires 12/15-lipoxygenase.

Mikule K, Gatlin JC, de la Houssaye BA, Pfenninger KH.

J Neurosci. 2002 Jun 15;22(12):4932-41.

15.

Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.

Ross S, Essary B, de la Houssaye BA, Pan Z, Mikule K, Mubarak O, Pfenninger KH.

Cell Growth Differ. 2000 Jan;11(1):19-30.

16.

Thrombin-induced growth cone collapse: involvement of phospholipase A(2) and eicosanoid generation.

de La Houssaye BA, Mikule K, Nikolic D, Pfenninger KH.

J Neurosci. 1999 Dec 15;19(24):10843-55.

17.

SRC binding to the cytoskeleton, triggered by growth cone attachment to laminin, is protein tyrosine phosphatase-dependent.

Helmke S, Lohse K, Mikule K, Wood MR, Pfenninger KH.

J Cell Sci. 1998 Aug;111 ( Pt 16):2465-75.

18.

Clusters of lymphoma in ferrets.

Erdman SE, Kanki PJ, Moore FM, Brown SA, Kawasaki TA, Mikule KW, Travers KU, Badylak SF, Fox JG.

Cancer Invest. 1996;14(3):225-30.

PMID:
8630683

Supplemental Content

Loading ...
Support Center